ClinicalTrials.gg
CompletedNCT04285567CRISTALLOUpdated Mar 3, 2026Results posted

A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation

A Phase 3 interventional study of Obinutuzumab and Venetoclax in Chronic Lymphocytic Leukemia (CLL), sponsored by Hoffmann-La Roche. Completed at 40 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-03.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
166
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 53 studies testing obinutuzumab in Leukemia, Lymphocytic, Chronic, B-Cell — 16 open to participants now, 28 under way, 6 of them phase 3. obinutuzumab · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
14th of 53
166 · median 72
Started
2020
with 5 others
Phase 3
13 of 53
4 open now
Registered
31st of 53
by date
Lead sponsor
6 of 53
Hoffmann-La Roche

Among the 53 studies testing obinutuzumab in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 14th largest by enrollment, is one of 6 that started in 2020, is one of 13 in phase 3, and was the 31st registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

16 of the 53 studies testing obinutuzumab in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About obinutuzumab

obinutuzumab: first FDA approval 2013 (GAZYVA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies testing obinutuzumab in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of venetoclax and obinutuzumab (VEN + G) compared with fludarabine + cyclophosphamide + rituximab or bendamustine + rituximab (FCR/BR) in FIT participants (FIT is defined by a cumulative illness rating scale [CIRS]/score of ≤6 and a normal creatinine clearance of ≥70 mL/min) with previously untreated CLL without DEL(17P) or TP53 mutation requiring treatment. Eligible participants will be randomly assigned in a 1:1 ratio to receive either VEN + G (Arm A) or FCR/BR (Arm B).

03

Conditions studied

  • Chronic Lymphocytic Leukemia (CLL)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to comply with the study protocol, in the investigator's judgment
  • Aged 18 years or older
  • Have previously untreated documented Chronic Lymphocytic Leukemia (CLL) according to the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria
  • CLL requiring treatment according to the iwCLL criteria
  • Cumulative Illness Rating Scale (CIRS) score ≤ 6 and (CrCl) ≥ 70 mL/min
  • Hematology values within the following limits, unless cytopenia is caused by the underlying disease (i.e., no evidence of additional bone marrow (BM) dysfunction; e.g., myelodysplastic syndrome, hypoplastic BM):

    • ≥ 1.0 x 109/L, unless there is BM involvement
    • count ≥ 75 x 109/L and more than 7 days since last transfusion, or ≥ 30 x 109/L if there is BM involvement
  • Adequate liver function as indicated by a total , , and Alanine transaminase ≤ 2 times the institutional (ULN) value, unless directly attributable to the participant's CLL
  • >6 months
  • For women of : agreement to remain abstinent (refrain from heterosexual intercourse) or use and agreement to refrain from donating eggs
  • For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods, and agreement to refrain from donating sperm

Exclusion criteria

Exclusion Criteria:

  • Transformation of CLL to aggressive Non-Hodgkin's Lymphoma (NHL)
  • Participants with Small Lymphocyclic Lymphoma (SLL) only
  • Known central nervous system involvement
  • Participants with a history of confirmed progressive multifocal leukoencephalopathy (PML)
  • Detected del(17p) or TP53 mutation (valid test within 6-months from screening is required for randomisation)
  • An individual organ/system impairment score of 4 as assessed by the Cumulative Illness Rating Scale (CIRS) definition limiting the ability to receive the treatment regimen of this trial with the exception of eyes, ears, nose, throat organ system
  • Participants with uncontrolled hemolytic anemia or immune thrombocytopenia
  • History of prior
  • Participants with infections requiring IV treatment (Grade 3 or 4) within the last 8 weeks prior to enrollment
  • Evidence of other uncontrolled conditions including but not limited to active or uncontrolled systemic infection (e.g., viral, bacterial, or fungal)
  • History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products
  • to fludarabine, bendamustine, cyclophosphamide, rituximab, obinutuzumab, or venetoclax or to any of the (e.g., trehalose)
  • Pregnant women and nursing mothers
  • Vaccination with a ≤ 28 days prior to randomization
  • Prisoners or participants who are institutionalized by regulatory or court order or persons who are in dependence to the Sponsor or an investigator
  • History of illicit drug or alcohol abuse within 12 months prior to screening, in the investigator's judgment
  • Positive test results for chronic virus (HBV) infection (defined as positive hepatitis B surface antigen [HBsAg] serology)
  • Positive test result for (hepatitis C virus [HCV] antibody serology testing)
  • Participants with known infection with or Human T-Cell Leukemia Virus 1 (HTLV-1)
  • Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the participant's safe participation in and completion of the study
  • Received any of the following agents within 28 days prior to the first dose of study treatment:

    • Immunotherapy
    • Radiotherapy
    • Hormone therapy
    • Any therapies intended for the treatment of lymphoma/leukemia whether approved or experimental
  • Participants who have received the following agents:

    • Strong and moderate inhibitors/inducers within 7 days prior to the initiation of study treatment
    • therapy for anti-neoplastic intent with the exception of inhaled steroids for asthma, topical steroids, or replacement/stress corticosteroids within 7 days prior to the first dose of study drug administration
    • Consumed grapefruit, grapefruit products, Seville oranges(including marmalade containing Seville oranges), or star fruit within 3 days prior to the first dose of study drug and throughout venetoclax administration
  • Inability to swallow a large number of tablets.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
166 participants (actual)

Study arms

  • Experimental
    VEN + G

    Participants will receive 12 cycles of treatment (each cycle is 28 days). Venetoclax (VEN) will be administered orally, daily, with a 5-week ramp-up period, starting on Cycle 1, Day 22 and administration will continue until the end of Cycle 12. Obinutuzumab (G) will be administered intravenously (IV) on Days 1 (and 2), 8, and 15 of Cycle 1 and on Day 1 of Cycles 2-6.

    Drug: Obinutuzumab · Drug: Venetoclax

  • Active comparator
    FCR/BR

    Participants will receive 6 cycles of Fludarabine + Cyclophosphamide + Rituximab (FCR) consisting of a single cycle of a single infusion of rituximab on Day 1 and fludarabine and cyclophosphamide infusions on Days 1-3 of each 28-day cycle or bendamustine (B) as infusions on Days 1 and 2 and a single cycle of rituximab on Day 1 of each 28-day cycle.

    Drug: Fludarabine · Drug: Cyclophosphamide · Drug: Rituximab · Drug: Bendamustine

Interventions

  • Obinutuzumab 1000 milligrams (mg) will be administered IV on Days 1 (and 2), 8, and 15 of Cycle 1 and on Day 1 of Cycles 2-6.

    Also known as: Gazyva, RO5072759, GA101

  • Venetoclax 20 mg will be administered orally, once daily starting on Day 22 of Cycle 1 for 7 days, then ramp up from 50 to 400 mg/day during Cycle 2 and continue at 400 mg/day from Day 1 of Cycle 3 till end of Cycle 12.

    Also known as: Venclexta, RO5537382, GDC-0199

  • Fludarabine will be administered in a dosage of 25 milligram per meter squared (mg/m\^2), IV, on days 1, 2, and 3 of Cycles 1-6.

  • Cyclophosphamide will be administered in a dosage of 250 mg/m\^2, IV, on Days 1, 2, and 3 Cycles 1-6.

  • Rituximab will be administered at a dose of 375 mg/m\^2, IV, on Cycle 1, Day 1 followed by 500 mg/m\^2 on Day 1 of Cycles 2-6.

    Also known as: MabThera, Rituxan

  • Bendamustine will be administered at a dose of 90 mg/m\^2, IV, on 2 consecutive days of Cycles 1-6.

    Also known as: Treanda, Levact, Ribomustin

06

What researchers measure

Primary outcomes

  1. Minimal Residual Disease (MRD) Response Rate Measured in Peripheral Blood (PB) Using Next Generation Sequencing (NGS)

    MRD response rate was determined as the percentage of participants with MRD-negativity measured in the PB using NGS using a cutoff of \< 10\^-4. MRD was considered negative if the result was \< 1 CLL cell in 10,000 leukocytes. Percentages have been rounded off to the nearest decimal point.

    Time frame: At Month 15

Secondary outcomes

  1. Progression-free Survival (PFS)

    PFS was defined as the time from randomization to the first occurrence of disease progression (PD), or death from any cause. PD was assessed by the investigators using the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria. PD was defined as any one of the following: Appearance of any new lesion such as enlarged lymph nodes (≥ 1.5 centimeters \[cm\]); increase by ≥ 50% in greatest diameter of any previous site (≥ 1.5 cm); increase in the spleen/liver size by ≥ 50% or de novo appearance of splenomegaly/hepatomegaly; increase in blood lymphocytes by 50% or more with at least 5x10\^9/litres (L) B lymphocytes; transformation to a more aggressive histology; occurrence of cytopenia; post treatment: progression of any cytopenia, documented by a decrease of hemoglobin (Hb) ≥ 2 grams per deciliter (g/dL) or 10 g/dL, or by a decrease of platelet counts ≥ 50%/100x10\^9/L, which occurs at least 3 months after treatment. Kaplan-Meier (K-M) method was used to determine PFS.

    Time frame: Up to approximately 56.4 months

  2. MRD Response Rate in PB of FCR/BR Compared With VEN+G at the End of Treatment Response Visit

    MRD response rate was determined as the percentage of participants with MRD-negativity measured in the PB using NGS using a cutoff of \< 10\^-4. MRD was considered negative if the result was \< 1 CLL cell in 10,000 leukocytes. Percentages have been rounded off to the nearest decimal point.

    Time frame: VEN+G: From Cycle 1 Day 1 up to 15 months; FCR/BR: From Cycle 1 Day 1 up to 9 months (1 cycle=28 days)

  3. MRD Response Rate in Bone Marrow (BM) of FCR/BR Compared With VEN+G at the End of Treatment Response Visit

    MRD response rate=percentage of participants with MRD-negativity measured in BM using NGS (cutoff of \<10\^-4). MRD negativity=\<1 CLL cell in 10,000 leukocytes. MRD in BM was assessed for participants with complete response (CR)/CR with incomplete blood count recovery (CRi) \& partial response (PR). CR=PB lymphocytes \<4x10\^9 /L; Absence of significant lymphadenopathy (nodes \<1.5 cm in longest diameter); no hepatomegaly/splenomegaly; absence of disease/constitutional symptoms; BM at least normocellular for age, ≤30% of nucleated cells being lymphocytes. CRi=fulfilling CR criteria but with persistent anemia/thrombocytopenia/neutropenia. PR= ≥50% decrease in PB lymphocyte count from pre-treatment value; ≥50% reduction in lymphadenopathy (sum of longest diameter of up to 6 largest lymph nodes by physical exam \& 50% reduction in the sum of product of the diameter of up to 6 largest lymph nodes); ≥50% reduction of liver/spleen enlargement/normalization in size, if enlarged at baseline.

    Time frame: VEN+G: From Cycle 1 Day 1 up to 15 months; FCR/BR: From Cycle 1 Day 1 up to 9 months (1 cycle=28 days)

  4. Objective Response Rate (ORR)

    ORR was defined as the percentage of participants with overall response (OR) of CR, CRi, and PR as determined by the investigator according to the iwCLL guidelines. CR was defined as PB lymphocytes \<4x10\^9 /L; absence of significant lymphadenopathy (nodes \<1.5 cm in longest diameter \[LD\]); no hepatomegaly/splenomegaly; absence of disease/constitutional symptoms; BM at least normocellular for age, ≤30% of nucleated cells being lymphocytes. CRi was defined as fulfilling CR criteria but with persistent anemia/thrombocytopenia/neutropenia. PR was defined as ≥50% decrease in PB lymphocyte count from pre-treatment value; ≥50% reduction in lymphadenopathy sum of longest diameter of up to 6 largest lymph nodes by physical exam and 50% reduction in the sum of product of the diameter of up to 6 largest lymph nodes); ≥50% reduction of liver/spleen enlargement/normalization in size, if enlarged at baseline.

    Time frame: At Month 15

  5. CR Rate

    CR rate was defined as the percentage of participants with CR or CRi. CR/CRi were defined according to the iwCLL guidelines. CR was defined as one of the following: PB lymphocytes (evaluated by blood and differential count) below 4 x 10\^9 /L; absence of significant lymphadenopathy (nodes \< 1.5 cm in LD or any extra nodal disease); no hepatomegaly; no splenomegaly; absence of disease or constitutional symptoms; BM at least normocellular for age, ≤30% of nucleated cells being lymphocytes. CRi was defined as participants fulfilling CR criteria but had persistent anemia, thrombocytopenia, or neutropenia. Percentages have been rounded off to the nearest decimal point.

    Time frame: At Month 15

  6. MRD Response Rate in PB of Participants With a CR/CRi at the End of Treatment Visit

    MRD response rate was determined as the percentage of participants (with a CR/CRi) with MRD-negativity measured in the PB using NGS using a cutoff of \< 10\^-4. MRD was considered negative if the result was \< 1 CLL cell in 10,000 leukocytes. CR/CRi were defined according to the iwCLL guidelines. CR was defined as one of the following: PB lymphocytes below 4 x 10\^9 /L; absence of significant lymphadenopathy (nodes \< 1.5 cm in LD or any extra nodal disease); no hepatomegaly; no splenomegaly; absence of disease or constitutional symptoms; BM at least normocellular for age, ≤30% of nucleated cells being lymphocytes. CRi was defined as participants fulfilling CR criteria but had persistent anemia, thrombocytopenia, or neutropenia. Percentages have been rounded off to the nearest decimal point.

    Time frame: At Month 15

  7. MRD Response Rate in BM of Participants With a CR/CRi at the End of Treatment Visit

    MRD response rate was determined as the percentage of participants (with CR/CRi) with MRD-negativity measured in the BM using NGS using a cutoff of \< 10\^-4. MRD was considered negative if the result was \< 1 CLL cell in 10,000 leukocytes. CR/CRi were defined according to the iwCLL guidelines. CR was defined as one of the following: PB lymphocytes below 4 x 10\^9 /L; absence of significant lymphadenopathy (nodes \< 1.5 cm in LD or any extra nodal disease); no hepatomegaly; no splenomegaly; absence of disease or constitutional symptoms; BM at least normocellular for age, ≤30% of nucleated cells being lymphocytes. CRi was defined as participants fulfilling CR criteria with CR but had persistent anemia, thrombocytopenia, or neutropenia. Percentages have been rounded off to the nearest decimal point.

    Time frame: VEN+G: From Cycle 1 Day 1 up to 15 months; FCR/BR: From Cycle 1 Day 1 up to 9 months (1 cycle=28 days)

  8. Duration of Objective Response (DOR)

    DOR=time from first occurrence of a documented objective response (CR, CRi \& PR) to the time of PD as determined by the investigator, or death from any cause, whichever occurred first. CR, CRi, PR, \& PD were defined per the iwCLL guidelines. PD = any one of the following: appearance of any new lesion such as enlarged lymph nodes (≥ 1.5 cm); increase by ≥ 50% in greatest diameter of any previous site (≥ 1.5 cm); increase in the spleen/liver size by ≥ 50% or de novo appearance of splenomegaly/hepatomegaly; increase in blood lymphocytes by 50% or more with at least 5x10\^9/L B lymphocytes; transformation to a more aggressive histology; occurrence of cytopenia; posttreatment: progression of any cytopenia, documented by a decrease of Hb ≥ 2 g/dL or 10 g/dL, or by a decrease of platelet counts ≥ 50%/100x10\^9/L, which occurs at least 3 months after treatment. CR, CRi \& PR were defined as outlined in the description for ORR outcome measure. K-M method was used to determine DOR.

    Time frame: Up to approximately 56.4 months

  9. Best Overall Response (BOR)

    BOR=percentage of participants with CR/CRi/PR/stable disease (SD)/PD per the investigator. Participants with best response as CR/CRi/PR were considered responders while those reaching SD/PD were non-responders. SD=participants who have not achieved a CR or a PR, or who have not exhibited PD. PD=any one of the following: appearance of any new lesion such as enlarged lymph nodes (≥ 1.5 cm); increase by ≥ 50% in greatest diameter of any previous site (≥ 1.5 cm); increase in the spleen/liver size by ≥ 50% or de novo appearance of splenomegaly/hepatomegaly; increase in blood lymphocytes by 50% or more with at least 5x10\^9/L B lymphocytes; transformation to a more aggressive histology; occurrence of cytopenia; posttreatment: progression of any cytopenia, documented by a decrease of Hb ≥ 2 g/dL or 10 g/dL, or by a decrease of platelet counts ≥ 50%/100x10\^9/L, which occurs at least 3 months after treatment. CR, CRi and PR were defined as outlined in the description for ORR, OM number 5.

    Time frame: At Month 15

  10. Event-free Survival (EFS)

    EFS was defined as the time between the date of randomization and the date of PD/relapse, death, or the start of a new anti-leukemic therapy. PD was defined as any one of the following: appearance of any new lesion such as enlarged lymph nodes (≥ 1.5 cm); increase by ≥ 50% in greatest diameter of any previous site (≥ 1.5 cm); increase in the spleen/liver size by ≥ 50% or de novo appearance of splenomegaly/hepatomegaly; increase in blood lymphocytes by 50% or more with at least 5x10\^9/L B lymphocytes; transformation to a more aggressive histology; occurrence of cytopenia; posttreatment: progression of any cytopenia, documented by a decrease of Hb ≥ 2 g/dL or 10 g/dL, or by a decrease of platelet counts ≥ 50%/100x10\^9/L, which occurs at least 3 months after treatment. K-M method was used to determine EFS.

    Time frame: Up to approximately 56.4 months

  11. Overall Survival (OS)

    OS was defined as the time between the date of randomization and the date of death due to any cause. K-M method was used to determine OS.

    Time frame: Up to approximately 56.4 months

  12. VEN + G: Tumor Lysis Syndrome (TLS) Risk Reduction Rate

    TLS risk reduction rate in the VEN + G arm was defined as the reduction in the percentage of participants who were TLS high-risk after 3 doses of obinutuzumab compared to the percentage of participants who were TLS high-risk at baseline. Risk for developing TLS were categorised into: Low - All measurable lymph nodes with the LD \< 5 cm and \< 25x10\^9/L absolute lymphocyte count (ALC); Medium - Any measurable lymph node with the LD ≥5 cm but \<10 cm OR ≥25x10\^9/L ALC; High - Any measurable lymph node with the LD ≥10 cm or the presence of both ≥25x10\^9/L ALC and any measurable lymph node with the LD ≥5 cm but \<10 cm. Percentages have been rounded off to the nearest decimal point.

    Time frame: Baseline up to Cycle 1 Day 22 (1 cycle=28 days)

  13. VEN + G: Reduction in Mandatory Hospitalizations During Venetoclax Ramp-up

    Reduction in mandatory hospitalizations during venetoclax ramp-up in the VEN + G arm participants was defined as the actual number of protocol-mandated hospitalizations for TLS monitoring during venetoclax ramp-up period after 3 doses of obinutuzumab compared to the number of protocol-mandated hospitalizations for TLS monitoring during venetoclax ramp-up expected at baseline. Ramp-up period for venetoclax was defined as period from Cycle 1, Days 22-28, and Cycle 2, Day 1-Day 7 where the 20 mg and 50 mg daily doses of venetoclax, were administered for participants at TLS-high risk requiring mandated hospitalizations (the hospitalizations at 100, 200 and 400 was only needed if the participant had a TLS event at one of the lower doses). Total number of hospitalizations in high-risk TLS participants at baseline (expected to be N=2 hospitalization) was compared with the number of protocol mandated hospitalizations during the first 2 doses of the ramp-up.

    Time frame: Cycle 1 Days 22-28 up to Cycle 2 Days 1-7 (1 cycle=28 days)

  14. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE was any AE that meets any of the following criteria: is fatal; is life-threatening; requires or prolongs inpatient hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to study drug; is a significant medical event in the investigator's judgment.

    Time frame: Up to approximately 56.4 months

  15. Number of Participants With Premature Withdrawals Due to AEs

    An AE was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Participants who withdrew from the study due to AEs are being reported here.

    Time frame: Up to approximately 56.4 months

  16. Change From Baseline in Physical Functioning Assessed Using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQC-30)

    The EORTC QLQ-C30 consists of 30 questions incorporated into 5 functional scales (physical, role, cognitive, emotional and social scales), 3 symptom scales (fatigue, pain, nausea, and vomiting scales), a global health status/global quality-of-life (GHS/QoL) scale, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The functioning items were scored on a 4-point scale (1=Not at All to 4=Very Much). Raw average scale scores were linearly transformed to range from 0-100. Higher scores=higher response levels (i.e. higher functioning). FAS. Overall number analyzed=participants with data available for analysis. Number analyzed includes all with data at a given timepoint. Time frame continued: Day 28 After Completion/Early Termination (ET) of Combination Therapy (VEN+G)/Day 28 After Treatment Completion (TC)/ET (FCR/BR)=Up to approximately 5.6 months; Change at Day 28 After TC/EC of Ven Monotherapy=Up to approximately 11 months.

    Time frame: Baseline, Day 22 of Cycle 1; Days 1, 2, 3 & 22 of Cycle 2; Days 1 & 2 of Cycles 3, 4, 5; Day 1 of Cycles 6, 7, 8, 9, 10, 11 & 12; Follow-up (FU) at Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 (1 cycle = 28 days)

  17. Change From Baseline in Role Functioning Assessed Using EORTC QLQC-30

    The EORTC QLQ-C30 consists of 30 questions incorporated into five functional scales (physical, role, cognitive, emotional and social scales), three symptom scales (fatigue, pain, nausea, and vomiting scales), a GHS/QoL scale, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The functioning items were scored on a 4-point scale (1=Not at All to 4=Very Much). Raw average scale scores were linearly transformed to range 0-100 with higher scores indicating higher response levels (i.e. higher functioning). FAS. Overall number analyzed=participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at a given timepoint. Time frame continued: Day 28 After Completion/ ET of Combination Therapy (VEN+G)/Day 28 After TC/ET (FCR/BR)=Up to approximately 5.6 months; Change at Day 28 After TC/EC of Ven Monotherapy=Up to approximately 11 months.

    Time frame: Baseline, Day 22 of Cycle 1; Days 1, 2, 3 & 22 of Cycle 2; Days 1 & 2 of Cycles 3, 4, 5; Day 1 of Cycles 6, 7, 8, 9, 10, 11 & 12; FU at Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 (1 cycle = 28 days)

  18. Change From Baseline in GHS/QoL Assessed Using EORTC QLQC-30

    The EORTC QLQ-C30 consists of 30 questions incorporated into five functional scales (physical, role, cognitive, emotional and social scales), three symptom scales (fatigue, pain, nausea, and vomiting scales), a GHS/QoL scale, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The 2 GHS/QoL items were scored on a 7-point scale (1= Very poor to 7=Excellent). Raw average scale scores were linearly transformed to range 0-100 with higher scores indicating higher response levels (i.e. better QoL). FAS. Overall number analyzed=participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at a given timepoint. Time frame continued (TFC): Day 28 After Completion/ET of Combination Therapy (VEN+G)/Day 28 After TC/ET (FCR/BR)=Up to approximately (approx) 5.6 months; Change at Day 28 After TC/EC of Ven Monotherapy=Up to approximately 11 months.

    Time frame: Baseline, Day 22 of Cycle 1; Days 1, 2, 3 & 22 of Cycle 2; Days 1 & 2 of Cycles 3, 4, 5; Day 1 of Cycles 6, 7, 8, 9, 10, 11 & 12; FU at Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 (1 cycle = 28 days)

  19. Change From Baseline in Mean Core Symptom Severity Score as Measured by the M.D. Anderson Symptom Inventory (MDASI-CLL)

    MDASI-CLL=25 items over 3 scales assessing core cancer \& CLL-related symptom severity \&symptom interference that a participant may have experienced in past 24 hours. Participants rated severity of 13 symptoms called mean core symptom severity (pain, fatigue, nausea, disturbed sleep, distressed, shortness of breath, remembering things, lack of appetite, drowsy, dry mouth, sadness, vomiting \& numbness/tingling) to assess mean core symptom severity score. Each symptom is scored from 0 (not present)-10 (as bad as you can imagine). Total score across all questions(0-130) was divided by number of questions. Mean score, ranged from 0-10. Lower scores=lower symptom severity. FAS. Overall number analyzed=participants with data available for analysis. Number analyzed includes all with data at a given timepoint. TFC: Day 28 After Completion/ET of Combination Therapy (VEN+G)/Day 28 After TC/ET (FCR/BR)=Up to approx 5.6 months; Change at Day 28 After TC/EC of Ven Monotherapy=Up to approx11 months.

    Time frame: Baseline, Day 22 of Cycle 1; Days 1, 2, & 22 of Cycle 2; Days 1 & 2 of Cycles 3, 4, 5; Day 1 of Cycles 6, 7, 8, 9, 10, 11 & 12; FU at Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 (1 cycle = 28 days)

  20. Change From Baseline in Mean Module Symptom Severity Score as Measured by MDASI-CLL

    MDASI-CLL=25 items over 3 scales that assess core cancer \& CLL-related symptom severity, as well as symptom interference a participant may have experienced in past 24 hours. Participants were asked to rate the severity of 6 disease-specific symptoms called mean module symptom severity (night sweats, fever \& chills, lymph node swelling, diarrhea, easy bruising/bleeding \& constipation). Each symptom is scored on scale from 0-10, where 0=not present \& 10=as bad as you can imagine. The total score across all questions (0 to 60) was divided by the number of questions. The mean score, therefore, ranged from 0-10. Higher scores indicated more symptom severity. FAS. Overall number analyzed=participants with data available for analysis. Number analyzed includes all with data at a given timepoint. Time frame continued: Day 28 After Completion/ET of VEN+G/Day 28 After TC/ET (FCR/BR)=Up to approximately 5.6 months; Change at Day 28 After TC/EC of Ven Monotherapy=Up to approximately 11 months.

    Time frame: Baseline, Day 22 of Cycle 1; Days 1, 2, & 22 of Cycle 2; Days 1 & 2 of Cycles 3, 4, 5; Day 1 of Cycles 6, 7, 8, 9, 10, 11 & 12; FU at Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 (1 cycle = 28 days)

  21. Change From Baseline in Mean Interference Score as Measured by MDASI-CLL

    MDASI-CLL consists of 25 items over 3 scales that assess core cancer \& CLL-related symptom severity, and symptom interference that a participant may have experienced in past 24 hours. Participants rated 6 mean interference on life questions (general activity, walking, work, mood, relations with other people \& enjoyment of life) to derive the Mean Interference Score. These were scored on a scale from 0 (symptom did not interfere)-10 (symptom interfered completely). Total score across all questions (0 to 60) was divided by number of questions. Mean score, therefore, ranged from 0-10. Higher scores=higher symptom interference. FAS. Overall number analyzed=participants with data available for analysis. Number analyzed=participants with data available for analysis at a given timepoint. Time frame continued: Day 28 After Completion/ ET of Combination Therapy (VEN+G)/Day 28 After TC/ET (FCR/BR)=Up to approx 5.6 months; Change at Day 28 After TC/EC of Ven Monotherapy=Up to approx 11 months.

    Time frame: Baseline, Day 22 of Cycle 1; Days 1, 2, & 22 of Cycle 2; Days 1 & 2 of Cycles 3, 4, 5; Day 1 of Cycles 6, 7, 8, 9, 10, 11 & 12; FU at Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 (1 cycle = 28 days)

07

Results

Posted Apr 17, 2025

Participant flow

A total of 166 participants with previously untreated chronic lymphocytic leukemia (CLL) without del (17p) or tumor protein p53 (TP53) mutation took part in the study at 38 investigative sites in France, Italy, Australia, Spain, and the United States from 28 May 2020 to 19 March 2025. The study is considered "Completed" because all the pre-planned study activities and analyses have been performed.

Participant flow — Overall Study
MilestoneArm A: VEN+GArm B: FCR/BR
Started8086
Safety population7785
Completed00
Not completed8086
Withdrew: Adverse event11
Withdrew: Death33
Withdrew: Lost to follow-up11
Withdrew: Reason not specified22
Withdrew: Physician decision21
Withdrew: Study ended by sponsor6972
Withdrew: Withdrawal by subject26

Outcome measures

PrimaryMinimal Residual Disease (MRD) Response Rate Measured in Peripheral Blood (PB) Using Next Generation Sequencing (NGS)

MRD response rate was determined as the percentage of participants with MRD-negativity measured in the PB using NGS using a cutoff of \< 10\^-4. MRD was considered negative if the result was \< 1 CLL cell in 10,000 leukocytes. Percentages have been rounded off to the nearest decimal point.

Time frame:
At Month 15
Reported as:
Number · percentage of participants
Minimal Residual Disease (MRD) Response Rate Measured in Peripheral Blood (PB) Using Next Generation Sequencing (NGS)
percentage of participantsArm A: VEN+GArm B: FCR/BR
Minimal Residual Disease (MRD) Response Rate Measured in Peripheral Blood (PB) Using Next Generation Sequencing (NGS)81.3 (70.97 to 89.11)54.7 (43.55 to 65.42)
Statistical analysis
  • Arm A: VEN+G vs Arm B: FCR/BR · Cochran-Mantel-Haenszel · p = 0.0004 · Difference in rates: 26.60 · 95% CI 12.33 to 40.8795% CI for difference in rates were constructed using Anderson-Hauck method.
SecondaryProgression-free Survival (PFS)

PFS was defined as the time from randomization to the first occurrence of disease progression (PD), or death from any cause. PD was assessed by the investigators using the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria. PD was defined as any one of the following: Appearance of any new lesion such as enlarged lymph nodes (≥ 1.5 centimeters \[cm\]); increase by ≥ 50% in greatest diameter of any previous site (≥ 1.5 cm); increase in the spleen/liver size by ≥ 50% or de novo appearance of splenomegaly/hepatomegaly; increase in blood lymphocytes by 50% or more with at least 5x10\^9/litres (L) B lymphocytes; transformation to a more aggressive histology; occurrence of cytopenia; post treatment: progression of any cytopenia, documented by a decrease of hemoglobin (Hb) ≥ 2 grams per deciliter (g/dL) or 10 g/dL, or by a decrease of platelet counts ≥ 50%/100x10\^9/L, which occurs at least 3 months after treatment. Kaplan-Meier (K-M) method was used to determine PFS.

Time frame:
Up to approximately 56.4 months
Reported as:
Median · months
Progression-free Survival (PFS)
monthsArm A: VEN+GArm B: FCR/BR
Progression-free Survival (PFS)NA (NA to NA)53.3 (NA to NA)
Statistical analysis
  • Arm A: VEN+G vs Arm B: FCR/BR · Log Rank · p = 0.3999 · Hazard ratio (hr): 0.72 · 95% CI 0.34 to 1.54
SecondaryMRD Response Rate in PB of FCR/BR Compared With VEN+G at the End of Treatment Response Visit

MRD response rate was determined as the percentage of participants with MRD-negativity measured in the PB using NGS using a cutoff of \< 10\^-4. MRD was considered negative if the result was \< 1 CLL cell in 10,000 leukocytes. Percentages have been rounded off to the nearest decimal point.

Time frame:
VEN+G: From Cycle 1 Day 1 up to 15 months; FCR/BR: From Cycle 1 Day 1 up to 9 months (1 cycle=28 days)
Reported as:
Number · percentage of participants
MRD Response Rate in PB of FCR/BR Compared With VEN+G at the End of Treatment Response Visit
percentage of participantsArm A: VEN+GArm B: FCR/BR
MRD Response Rate in PB of FCR/BR Compared With VEN+G at the End of Treatment Response Visit81.3 (70.97 to 89.11)60.5 (49.34 to 70.85)
Statistical analysis
  • Arm A: VEN+G vs Arm B: FCR/BR · Cochran-Mantel-Haenszel · p = 0.0053 · Difference in rates: 20.78 · 95% CI 6.66 to 34.9095% CI for difference in rates were constructed using Anderson-Hauck method.
SecondaryMRD Response Rate in Bone Marrow (BM) of FCR/BR Compared With VEN+G at the End of Treatment Response Visit

MRD response rate=percentage of participants with MRD-negativity measured in BM using NGS (cutoff of \<10\^-4). MRD negativity=\<1 CLL cell in 10,000 leukocytes. MRD in BM was assessed for participants with complete response (CR)/CR with incomplete blood count recovery (CRi) \& partial response (PR). CR=PB lymphocytes \<4x10\^9 /L; Absence of significant lymphadenopathy (nodes \<1.5 cm in longest diameter); no hepatomegaly/splenomegaly; absence of disease/constitutional symptoms; BM at least normocellular for age, ≤30% of nucleated cells being lymphocytes. CRi=fulfilling CR criteria but with persistent anemia/thrombocytopenia/neutropenia. PR= ≥50% decrease in PB lymphocyte count from pre-treatment value; ≥50% reduction in lymphadenopathy (sum of longest diameter of up to 6 largest lymph nodes by physical exam \& 50% reduction in the sum of product of the diameter of up to 6 largest lymph nodes); ≥50% reduction of liver/spleen enlargement/normalization in size, if enlarged at baseline.

Time frame:
VEN+G: From Cycle 1 Day 1 up to 15 months; FCR/BR: From Cycle 1 Day 1 up to 9 months (1 cycle=28 days)
Reported as:
Number · percentage of participants
MRD Response Rate in Bone Marrow (BM) of FCR/BR Compared With VEN+G at the End of Treatment Response Visit
percentage of participantsArm A: VEN+GArm B: FCR/BR
MRD Response Rate in Bone Marrow (BM) of FCR/BR Compared With VEN+G at the End of Treatment Response Visit70.0 (58.72 to 79.74)38.4 (28.08 to 49.49)
Statistical analysis
  • Arm A: VEN+G vs Arm B: FCR/BR · Cochran-Mantel-Haenszel · p = < .0001 · Difference in rates: 31.63 · 95% CI 16.55 to 46.7195% CI for difference in rates were constructed using Anderson-Hauck method.
SecondaryObjective Response Rate (ORR)

ORR was defined as the percentage of participants with overall response (OR) of CR, CRi, and PR as determined by the investigator according to the iwCLL guidelines. CR was defined as PB lymphocytes \<4x10\^9 /L; absence of significant lymphadenopathy (nodes \<1.5 cm in longest diameter \[LD\]); no hepatomegaly/splenomegaly; absence of disease/constitutional symptoms; BM at least normocellular for age, ≤30% of nucleated cells being lymphocytes. CRi was defined as fulfilling CR criteria but with persistent anemia/thrombocytopenia/neutropenia. PR was defined as ≥50% decrease in PB lymphocyte count from pre-treatment value; ≥50% reduction in lymphadenopathy sum of longest diameter of up to 6 largest lymph nodes by physical exam and 50% reduction in the sum of product of the diameter of up to 6 largest lymph nodes); ≥50% reduction of liver/spleen enlargement/normalization in size, if enlarged at baseline.

Time frame:
At Month 15
Reported as:
Number · percentage of participants
Objective Response Rate (ORR)
percentage of participantsArm A: VEN+GArm B: FCR/BR
Objective Response Rate (ORR)88.8 (79.72 to 94.72)79.1 (68.95 to 87.10)
Statistical analysis
  • Arm A: VEN+G vs Arm B: FCR/BR · Cochran-Mantel-Haenszel · p = 0.1119 · Difference in response rates: 9.68 · 95% CI -2.05 to 21.4195% CI for difference in rates were constructed using Anderson-Hauck method.
SecondaryCR Rate

CR rate was defined as the percentage of participants with CR or CRi. CR/CRi were defined according to the iwCLL guidelines. CR was defined as one of the following: PB lymphocytes (evaluated by blood and differential count) below 4 x 10\^9 /L; absence of significant lymphadenopathy (nodes \< 1.5 cm in LD or any extra nodal disease); no hepatomegaly; no splenomegaly; absence of disease or constitutional symptoms; BM at least normocellular for age, ≤30% of nucleated cells being lymphocytes. CRi was defined as participants fulfilling CR criteria but had persistent anemia, thrombocytopenia, or neutropenia. Percentages have been rounded off to the nearest decimal point.

Time frame:
At Month 15
Reported as:
Number · percentage of participants
CR Rate
percentage of participantsArm A: VEN+GArm B: FCR/BR
CR Rate50.0 (38.60 to 61.40)32.6 (22.84 to 43.52)
Statistical analysis
  • Arm A: VEN+G vs Arm B: FCR/BR · Cochran-Mantel-Haenszel · p = 0.0154 · Difference in response rates: 17.44 · 95% CI 1.96 to 32.9395% CI for difference in rates were constructed using Anderson-Hauck method.
SecondaryMRD Response Rate in PB of Participants With a CR/CRi at the End of Treatment Visit

MRD response rate was determined as the percentage of participants (with a CR/CRi) with MRD-negativity measured in the PB using NGS using a cutoff of \< 10\^-4. MRD was considered negative if the result was \< 1 CLL cell in 10,000 leukocytes. CR/CRi were defined according to the iwCLL guidelines. CR was defined as one of the following: PB lymphocytes below 4 x 10\^9 /L; absence of significant lymphadenopathy (nodes \< 1.5 cm in LD or any extra nodal disease); no hepatomegaly; no splenomegaly; absence of disease or constitutional symptoms; BM at least normocellular for age, ≤30% of nucleated cells being lymphocytes. CRi was defined as participants fulfilling CR criteria but had persistent anemia, thrombocytopenia, or neutropenia. Percentages have been rounded off to the nearest decimal point.

Time frame:
At Month 15
Reported as:
Number · percentage of participants
MRD Response Rate in PB of Participants With a CR/CRi at the End of Treatment Visit
percentage of participantsArm A: VEN+GArm B: FCR/BR
MRD Response Rate in PB of Participants With a CR/CRi at the End of Treatment Visit97.5 (86.84 to 99.94)78.6 (59.05 to 91.70)
Statistical analysis
  • Arm A: VEN+G vs Arm B: FCR/BR · Cochran-Mantel-Haenszel · p = 0.0054 · Difference in rates: 18.93 · 95% CI 0.91 to 36.9595% CI for difference in rates were constructed using Anderson-Hauck method.
SecondaryMRD Response Rate in BM of Participants With a CR/CRi at the End of Treatment Visit

MRD response rate was determined as the percentage of participants (with CR/CRi) with MRD-negativity measured in the BM using NGS using a cutoff of \< 10\^-4. MRD was considered negative if the result was \< 1 CLL cell in 10,000 leukocytes. CR/CRi were defined according to the iwCLL guidelines. CR was defined as one of the following: PB lymphocytes below 4 x 10\^9 /L; absence of significant lymphadenopathy (nodes \< 1.5 cm in LD or any extra nodal disease); no hepatomegaly; no splenomegaly; absence of disease or constitutional symptoms; BM at least normocellular for age, ≤30% of nucleated cells being lymphocytes. CRi was defined as participants fulfilling CR criteria with CR but had persistent anemia, thrombocytopenia, or neutropenia. Percentages have been rounded off to the nearest decimal point.

Time frame:
VEN+G: From Cycle 1 Day 1 up to 15 months; FCR/BR: From Cycle 1 Day 1 up to 9 months (1 cycle=28 days)
Reported as:
Number · percentage of participants
MRD Response Rate in BM of Participants With a CR/CRi at the End of Treatment Visit
percentage of participantsArm A: VEN+GArm B: FCR/BR
MRD Response Rate in BM of Participants With a CR/CRi at the End of Treatment Visit87.5 (73.20 to 95.81)60.7 (40.58 to 78.50)
Statistical analysis
  • Arm A: VEN+G vs Arm B: FCR/BR · Cochran-Mantel-Haenszel · p = 0.0038 · Difference in rates: 26.79 · 95% CI 3.86 to 49.7295% CI for difference in rates were constructed using Anderson-Hauck method.
SecondaryDuration of Objective Response (DOR)

DOR=time from first occurrence of a documented objective response (CR, CRi \& PR) to the time of PD as determined by the investigator, or death from any cause, whichever occurred first. CR, CRi, PR, \& PD were defined per the iwCLL guidelines. PD = any one of the following: appearance of any new lesion such as enlarged lymph nodes (≥ 1.5 cm); increase by ≥ 50% in greatest diameter of any previous site (≥ 1.5 cm); increase in the spleen/liver size by ≥ 50% or de novo appearance of splenomegaly/hepatomegaly; increase in blood lymphocytes by 50% or more with at least 5x10\^9/L B lymphocytes; transformation to a more aggressive histology; occurrence of cytopenia; posttreatment: progression of any cytopenia, documented by a decrease of Hb ≥ 2 g/dL or 10 g/dL, or by a decrease of platelet counts ≥ 50%/100x10\^9/L, which occurs at least 3 months after treatment. CR, CRi \& PR were defined as outlined in the description for ORR outcome measure. K-M method was used to determine DOR.

Time frame:
Up to approximately 56.4 months
Reported as:
Median · months
Duration of Objective Response (DOR)
monthsArm A: VEN+GArm B: FCR/BR
Duration of Objective Response (DOR)NA (NA to NA)50.3 (50.3 to NA)
Statistical analysis
  • Arm A: VEN+G vs Arm B: FCR/BR · Log Rank · p = 0.4100 · Hazard ratio (hr): 0.72 · 95% CI 0.33 to 1.58
SecondaryBest Overall Response (BOR)

BOR=percentage of participants with CR/CRi/PR/stable disease (SD)/PD per the investigator. Participants with best response as CR/CRi/PR were considered responders while those reaching SD/PD were non-responders. SD=participants who have not achieved a CR or a PR, or who have not exhibited PD. PD=any one of the following: appearance of any new lesion such as enlarged lymph nodes (≥ 1.5 cm); increase by ≥ 50% in greatest diameter of any previous site (≥ 1.5 cm); increase in the spleen/liver size by ≥ 50% or de novo appearance of splenomegaly/hepatomegaly; increase in blood lymphocytes by 50% or more with at least 5x10\^9/L B lymphocytes; transformation to a more aggressive histology; occurrence of cytopenia; posttreatment: progression of any cytopenia, documented by a decrease of Hb ≥ 2 g/dL or 10 g/dL, or by a decrease of platelet counts ≥ 50%/100x10\^9/L, which occurs at least 3 months after treatment. CR, CRi and PR were defined as outlined in the description for ORR, OM number 5.

Time frame:
At Month 15
Reported as:
Number · percentage of participants
Best Overall Response (BOR)
percentage of participantsArm A: VEN+GArm B: FCR/BR
Best Overall Response (BOR)93.8 (86.01 to 97.94)90.7 (82.49 to 95.90)
Statistical analysis
  • Arm A: VEN+G vs Arm B: FCR/BR · Cochran-Mantel-Haenszel · p = 0.4199 · Difference in response rates: 3.05 · 95% CI -5.73 to 11.8495% CI for difference in rates were constructed using Anderson-Hauck method.
SecondaryEvent-free Survival (EFS)

EFS was defined as the time between the date of randomization and the date of PD/relapse, death, or the start of a new anti-leukemic therapy. PD was defined as any one of the following: appearance of any new lesion such as enlarged lymph nodes (≥ 1.5 cm); increase by ≥ 50% in greatest diameter of any previous site (≥ 1.5 cm); increase in the spleen/liver size by ≥ 50% or de novo appearance of splenomegaly/hepatomegaly; increase in blood lymphocytes by 50% or more with at least 5x10\^9/L B lymphocytes; transformation to a more aggressive histology; occurrence of cytopenia; posttreatment: progression of any cytopenia, documented by a decrease of Hb ≥ 2 g/dL or 10 g/dL, or by a decrease of platelet counts ≥ 50%/100x10\^9/L, which occurs at least 3 months after treatment. K-M method was used to determine EFS.

Time frame:
Up to approximately 56.4 months
Reported as:
Median · months
Event-free Survival (EFS)
monthsArm A: VEN+GArm B: FCR/BR
Event-free Survival (EFS)NA (NA to NA)53.3 (53.3 to NA)
Statistical analysis
  • Arm A: VEN+G vs Arm B: FCR/BR · Log Rank · p = 0.2078 · Hazard ratio (hr): 0.63 · 95% CI 0.30 to 1.31
SecondaryOverall Survival (OS)

OS was defined as the time between the date of randomization and the date of death due to any cause. K-M method was used to determine OS.

Time frame:
Up to approximately 56.4 months
Reported as:
Median · months
Overall Survival (OS)
monthsArm A: VEN+GArm B: FCR/BR
Overall Survival (OS)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Arm A: VEN+G vs Arm B: FCR/BR · Log Rank · p = 0.9468 · Hazard ratio (hr): 0.95 · 95% CI 0.19 to 4.71
SecondaryVEN + G: Tumor Lysis Syndrome (TLS) Risk Reduction Rate

TLS risk reduction rate in the VEN + G arm was defined as the reduction in the percentage of participants who were TLS high-risk after 3 doses of obinutuzumab compared to the percentage of participants who were TLS high-risk at baseline. Risk for developing TLS were categorised into: Low - All measurable lymph nodes with the LD \< 5 cm and \< 25x10\^9/L absolute lymphocyte count (ALC); Medium - Any measurable lymph node with the LD ≥5 cm but \<10 cm OR ≥25x10\^9/L ALC; High - Any measurable lymph node with the LD ≥10 cm or the presence of both ≥25x10\^9/L ALC and any measurable lymph node with the LD ≥5 cm but \<10 cm. Percentages have been rounded off to the nearest decimal point.

Time frame:
Baseline up to Cycle 1 Day 22 (1 cycle=28 days)
Reported as:
Number · percentage of participants
VEN + G: Tumor Lysis Syndrome (TLS) Risk Reduction Rate
percentage of participantsArm A: VEN+G
High-risk at Baseline23.8
High-risk at Cycle 1 Day 220
SecondaryVEN + G: Reduction in Mandatory Hospitalizations During Venetoclax Ramp-up

Reduction in mandatory hospitalizations during venetoclax ramp-up in the VEN + G arm participants was defined as the actual number of protocol-mandated hospitalizations for TLS monitoring during venetoclax ramp-up period after 3 doses of obinutuzumab compared to the number of protocol-mandated hospitalizations for TLS monitoring during venetoclax ramp-up expected at baseline. Ramp-up period for venetoclax was defined as period from Cycle 1, Days 22-28, and Cycle 2, Day 1-Day 7 where the 20 mg and 50 mg daily doses of venetoclax, were administered for participants at TLS-high risk requiring mandated hospitalizations (the hospitalizations at 100, 200 and 400 was only needed if the participant had a TLS event at one of the lower doses). Total number of hospitalizations in high-risk TLS participants at baseline (expected to be N=2 hospitalization) was compared with the number of protocol mandated hospitalizations during the first 2 doses of the ramp-up.

Time frame:
Cycle 1 Days 22-28 up to Cycle 2 Days 1-7 (1 cycle=28 days)
Reported as:
Number · number of hospitalizations
VEN + G: Reduction in Mandatory Hospitalizations During Venetoclax Ramp-up
number of hospitalizationsArm A: VEN+G
VEN + G: Reduction in Mandatory Hospitalizations During Venetoclax Ramp-up2
SecondaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE was any AE that meets any of the following criteria: is fatal; is life-threatening; requires or prolongs inpatient hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to study drug; is a significant medical event in the investigator's judgment.

Time frame:
Up to approximately 56.4 months
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsArm A: VEN+GArm B: FCR/BR
AEs7683
SAEs4642
SecondaryNumber of Participants With Premature Withdrawals Due to AEs

An AE was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Participants who withdrew from the study due to AEs are being reported here.

Time frame:
Up to approximately 56.4 months
Reported as:
Count of participants · Participants
Number of Participants With Premature Withdrawals Due to AEs
ParticipantsArm A: VEN+GArm B: FCR/BR
Number of Participants With Premature Withdrawals Due to AEs15
SecondaryChange From Baseline in Physical Functioning Assessed Using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQC-30)

The EORTC QLQ-C30 consists of 30 questions incorporated into 5 functional scales (physical, role, cognitive, emotional and social scales), 3 symptom scales (fatigue, pain, nausea, and vomiting scales), a global health status/global quality-of-life (GHS/QoL) scale, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The functioning items were scored on a 4-point scale (1=Not at All to 4=Very Much). Raw average scale scores were linearly transformed to range from 0-100. Higher scores=higher response levels (i.e. higher functioning). FAS. Overall number analyzed=participants with data available for analysis. Number analyzed includes all with data at a given timepoint. Time frame continued: Day 28 After Completion/Early Termination (ET) of Combination Therapy (VEN+G)/Day 28 After Treatment Completion (TC)/ET (FCR/BR)=Up to approximately 5.6 months; Change at Day 28 After TC/EC of Ven Monotherapy=Up to approximately 11 months.

Time frame:
Baseline, Day 22 of Cycle 1; Days 1, 2, 3 & 22 of Cycle 2; Days 1 & 2 of Cycles 3, 4, 5; Day 1 of Cycles 6, 7, 8, 9, 10, 11 & 12; Follow-up (FU) at Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 (1 cycle = 28 days)
Reported as:
Mean · score on a scale
Change From Baseline in Physical Functioning Assessed Using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQC-30)
score on a scaleArm A: VEN+GArm B: FCR/BR
Baseline88.77 ± 16.0988.33 ± 14.08
Change at Cycle 1 Day 22-6.67 ± NA—
Change at Cycle 2 Day 1-0.92 ± 9.050.30 ± 9.85
Change at Cycle 2 Day 2—8.89 ± 13.88
Change at Cycle 2 Day 3—-13.33 ± NA
Change at Cycle 2 Day 2213.33 ± NA—
Change at Cycle 3 Day 1-1.03 ± 11.23-1.47 ± 15.72
Change at Cycle 3 Day 2—0.00 ± NA
Change at Cycle 4 Day 10.00 ± 13.860.51 ± 13.32
Change at Cycle 4 Day 2—6.67 ± NA
Change at Cycle 5 Day 10.25 ± 14.32-0.83 ± 13.16
Change at Cycle 5 Day 2—-6.67 ± NA
Change at Cycle 6 Day 11.03 ± 15.07-0.97 ± 12.97
Change at Day 28 After Completion/Early Termination of Combination Visit6.67 ± 32.20—
Change at Day 28 After Treatment Completion Or Early Termination-10.00 ± 14.14-3.27 ± 17.59
Change at Cycle 7 Day 1-0.64 ± 18.31—
Change at Cycle 8 Day 10.95 ± 13.94—
Change at Cycle 9 Day 10.28 ± 14.87—
Change at Cycle 10 Day 10.99 ± 14.64—
Change at Cycle 11 Day 12.32 ± 13.57—
Change at Cycle 12 Day 11.04 ± 11.19—
Change at Day 28 After Treatment Completion/Early Termination of Ven Monotherapy-2.41 ± 18.60—
Change at FU Month 3-14.44 ± 38.970.00 ± 14.61
Change at FU Month 6-1.27 ± 19.600.61 ± 16.32
Change at FU Month 91.08 ± 18.090.65 ± 13.48
Change at FU Month 12-1.67 ± 18.470.31 ± 14.03
Change at FU Month 150.33 ± 16.47-1.05 ± 13.02
Change at FU Month 181.05 ± 13.820.21 ± 13.91
Change at FU Month 21-1.67 ± 17.101.43 ± 13.25
Change at FU Month 240.83 ± 18.991.98 ± 13.81
Change at FU Month 27—-0.33 ± 11.13
Change at FU Month 30-0.74 ± 5.21—
Change at FU Month 33—-2.22 ± 10.89
Change at FU Month 366.67 ± NA—
SecondaryChange From Baseline in Role Functioning Assessed Using EORTC QLQC-30

The EORTC QLQ-C30 consists of 30 questions incorporated into five functional scales (physical, role, cognitive, emotional and social scales), three symptom scales (fatigue, pain, nausea, and vomiting scales), a GHS/QoL scale, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The functioning items were scored on a 4-point scale (1=Not at All to 4=Very Much). Raw average scale scores were linearly transformed to range 0-100 with higher scores indicating higher response levels (i.e. higher functioning). FAS. Overall number analyzed=participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at a given timepoint. Time frame continued: Day 28 After Completion/ ET of Combination Therapy (VEN+G)/Day 28 After TC/ET (FCR/BR)=Up to approximately 5.6 months; Change at Day 28 After TC/EC of Ven Monotherapy=Up to approximately 11 months.

Time frame:
Baseline, Day 22 of Cycle 1; Days 1, 2, 3 & 22 of Cycle 2; Days 1 & 2 of Cycles 3, 4, 5; Day 1 of Cycles 6, 7, 8, 9, 10, 11 & 12; FU at Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 (1 cycle = 28 days)
Reported as:
Mean · score on a scale
Change From Baseline in Role Functioning Assessed Using EORTC QLQC-30
score on a scaleArm A: VEN+GArm B: FCR/BR
Baseline85.67 ± 20.2883.06 ± 23.67
Change at Cycle 1 Day 22-33.33 ± NA—
Change at Cycle 2 Day 1-3.59 ± 18.053.79 ± 18.97
Change at Cycle 2 Day 2—22.22 ± 25.46
Change at Cycle 2 Day 3—0.00 ± NA
Change at Cycle 2 Day 2216.67 ± NA—
Change at Cycle 3 Day 1-1.28 ± 16.121.33 ± 28.74
Change at Cycle 3 Day 2—0.00 ± NA
Change at Cycle 4 Day 1-0.98 ± 22.461.60 ± 26.66
Change at Cycle 4 Day 2—0.00 ± NA
Change at Cycle 5 Day 10.31 ± 21.312.08 ± 20.81
Change at Cycle 5 Day 2—-16.67 ± NA
Change at Cycle 6 Day 1-1.28 ± 27.780.69 ± 26.40
Change at Day 28 After Completion/Early Termination of Combination Visit-8.33 ± 21.52—
Change at Day 28 After Treatment Completion Or Early Termination-8.33 ± 11.79-1.02 ± 29.54
Change at Cycle 7 Day 1-5.13 ± 27.72—
Change at Cycle 8 Day 11.70 ± 23.38—
Change at Cycle 9 Day 1-2.08 ± 24.70—
Change at Cycle 10 Day 1-2.13 ± 24.48—
Change at Cycle 11 Day 13.62 ± 23.28—
Change at Cycle 12 Day 1-0.74 ± 22.46—
Change at Day 28 After Treatment Completion/Early Termination of Ven Monotherapy-4.63 ± 29.17—
Change at FU Month 3-19.44 ± 42.712.90 ± 27.29
Change at FU Month 6-1.98 ± 28.806.06 ± 30.23
Change at FU Month 92.25 ± 27.542.44 ± 25.16
Change at FU Month 121.25 ± 27.83-1.55 ± 28.13
Change at FU Month 150.00 ± 26.95-3.51 ± 19.05
Change at FU Month 183.07 ± 21.87-1.04 ± 26.07
Change at FU Month 21-4.17 ± 26.106.55 ± 24.57
Change at FU Month 242.08 ± 24.233.70 ± 26.69
Change at FU Month 27—2.50 ± 23.12
Change at FU Month 30-3.70 ± 20.03—
Change at FU Month 33—2.78 ± 19.48
Change at FU Month 360.00 ± NA—
SecondaryChange From Baseline in GHS/QoL Assessed Using EORTC QLQC-30

The EORTC QLQ-C30 consists of 30 questions incorporated into five functional scales (physical, role, cognitive, emotional and social scales), three symptom scales (fatigue, pain, nausea, and vomiting scales), a GHS/QoL scale, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The 2 GHS/QoL items were scored on a 7-point scale (1= Very poor to 7=Excellent). Raw average scale scores were linearly transformed to range 0-100 with higher scores indicating higher response levels (i.e. better QoL). FAS. Overall number analyzed=participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at a given timepoint. Time frame continued (TFC): Day 28 After Completion/ET of Combination Therapy (VEN+G)/Day 28 After TC/ET (FCR/BR)=Up to approximately (approx) 5.6 months; Change at Day 28 After TC/EC of Ven Monotherapy=Up to approximately 11 months.

Time frame:
Baseline, Day 22 of Cycle 1; Days 1, 2, 3 & 22 of Cycle 2; Days 1 & 2 of Cycles 3, 4, 5; Day 1 of Cycles 6, 7, 8, 9, 10, 11 & 12; FU at Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 (1 cycle = 28 days)
Reported as:
Mean · score on a scale
Change From Baseline in GHS/QoL Assessed Using EORTC QLQC-30
score on a scaleArm A: VEN+GArm B: FCR/BR
Baseline73.10 ± 19.4872.64 ± 21.48
Change at Cycle 1 Day 22-25.00 ± NA—
Change at Cycle 2 Day 12.78 ± 18.911.85 ± 19.45
Change at Cycle 2 Day 2—11.11 ± 34.69
Change at Cycle 2 Day 3—8.33 ± NA
Change at Cycle 2 Day 2233.33 ± NA—
Change at Cycle 3 Day 13.21 ± 19.68-0.50 ± 26.91
Change at Cycle 3 Day 2—-25.00 ± NA
Change at Cycle 4 Day 11.47 ± 21.711.12 ± 23.22
Change at Cycle 4 Day 2—-25.00 ± NA
Change at Cycle 5 Day 12.67 ± 23.612.95 ± 21.71
Change at Cycle 5 Day 2—-25.00 ± NA
Change at Cycle 6 Day 10.00 ± 26.51-2.43 ± 22.08
Change at Day 28 After Completion/Early Termination of Combination Visit4.17 ± 43.30—
Change at Day 28 After Treatment Completion or Early Termination0.00 ± 0.00-4.25 ± 22.38
Change at Cycle 7 Day 1-2.40 ± 20.90—
Change at Cycle 8 Day 11.36 ± 20.22—
Change at Cycle 9 Day 10.87 ± 20.28—
Change at Cycle 10 Day 10.71 ± 22.84—
Change at Cycle 11 Day 13.99 ± 26.04—
Change at Cycle 12 Day 14.07 ± 19.91—
Change at Day 28 After Treatment Completion/Early Termination of Ven Monotherapy-1.85 ± 27.10—
Change at FU Month 3-33.33 ± 32.061.45 ± 23.79
Change at FU Month 62.98 ± 22.682.65 ± 27.74
Change at FU Month 94.50 ± 24.26-1.02 ± 21.10
Change at FU Month 12-0.42 ± 24.89-0.39 ± 23.98
Change at FU Month 15-0.62 ± 23.30-2.19 ± 21.98
Change at FU Month 184.39 ± 20.113.39 ± 22.88
Change at FU Month 210.52 ± 21.997.44 ± 21.79
Change at FU Month 245.90 ± 22.453.70 ± 25.04
Change at FU Month 27—3.33 ± 21.86
Change at FU Month 302.78 ± 25.00—
Change at FU Month 33—6.94 ± 30.92
Change at FU Month 3616.67 ± NA—
SecondaryChange From Baseline in Mean Core Symptom Severity Score as Measured by the M.D. Anderson Symptom Inventory (MDASI-CLL)

MDASI-CLL=25 items over 3 scales assessing core cancer \& CLL-related symptom severity \&symptom interference that a participant may have experienced in past 24 hours. Participants rated severity of 13 symptoms called mean core symptom severity (pain, fatigue, nausea, disturbed sleep, distressed, shortness of breath, remembering things, lack of appetite, drowsy, dry mouth, sadness, vomiting \& numbness/tingling) to assess mean core symptom severity score. Each symptom is scored from 0 (not present)-10 (as bad as you can imagine). Total score across all questions(0-130) was divided by number of questions. Mean score, ranged from 0-10. Lower scores=lower symptom severity. FAS. Overall number analyzed=participants with data available for analysis. Number analyzed includes all with data at a given timepoint. TFC: Day 28 After Completion/ET of Combination Therapy (VEN+G)/Day 28 After TC/ET (FCR/BR)=Up to approx 5.6 months; Change at Day 28 After TC/EC of Ven Monotherapy=Up to approx11 months.

Time frame:
Baseline, Day 22 of Cycle 1; Days 1, 2, & 22 of Cycle 2; Days 1 & 2 of Cycles 3, 4, 5; Day 1 of Cycles 6, 7, 8, 9, 10, 11 & 12; FU at Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 (1 cycle = 28 days)
Reported as:
Mean · score on a scale
Change From Baseline in Mean Core Symptom Severity Score as Measured by the M.D. Anderson Symptom Inventory (MDASI-CLL)
score on a scaleArm A: VEN+GArm B: FCR/BR
Baseline1.75 ± 1.531.66 ± 1.50
Change at Cycle 1 Day 220.46 ± NA—
Change at Cycle 2 Day 1-0.43 ± 1.32-0.20 ± 1.49
Change at Cycle 2 Day 2—0.38 ± 0.98
Change at Cycle 2 Day 220.08 ± NA—
Change at Cycle 3 Day 1-0.33 ± 1.45-0.23 ± 1.37
Change at Cycle 3 Day 2—-0.23 ± NA
Change at Cycle 4 Day 1-0.27 ± 1.39-0.15 ± 1.51
Change at Cycle 4 Day 2—0.54 ± NA
Change at Cycle 5 Day 1-0.32 ± 1.44-0.08 ± 1.25
Change at Cycle 5 Day 2—2.46 ± NA
Change at Cycle 6 Day 1-0.41 ± 1.27-0.10 ± 1.58
Change at Day 28 After Completion/Early Termination of Combination Therapy0.25 ± 2.53—
Change at Day 28 After Treatment Completion or Early Termination0.23 ± 0.76-0.33 ± 1.74
Change at Cycle 7 Day 1-0.24 ± 1.63—
Change at Cycle 8 Day 1-0.55 ± 1.36—
Change at Cycle 9 Day 1-0.50 ± 1.39—
Change at Cycle 10 Day 1-0.42 ± 1.68—
Change at Cycle 11 Day 1-0.62 ± 1.45—
Change at Cycle 12 Day 1-0.39 ± 1.51—
Change at Day 28 After Treatment Completion/Early Termination of Ven Monotherapy-0.50 ± 1.55—
Change at FU Month 3-0.44 ± 2.73-0.37 ± 1.43
Change at FU Month 6-0.43 ± 1.69-0.48 ± 1.68
Change at FU Month 9-0.47 ± 1.61-0.23 ± 1.34
Change at FU Month 12-0.43 ± 1.60-0.28 ± 1.32
Change at FU Month 15-0.31 ± 1.52-0.18 ± 1.22
Change at FU Month 18-0.30 ± 1.36-0.36 ± 1.46
Change at FU Month 21-0.03 ± 1.48-0.34 ± 1.19
Change at FU Month 24-0.29 ± 1.68-0.48 ± 1.20
Change at FU Month 27—-0.49 ± 1.45
Change at FU Month 30-0.85 ± 1.94—
Change at FU Month 33—-0.36 ± 1.54
Change at FU Month 360.38 ± NA—
SecondaryChange From Baseline in Mean Module Symptom Severity Score as Measured by MDASI-CLL

MDASI-CLL=25 items over 3 scales that assess core cancer \& CLL-related symptom severity, as well as symptom interference a participant may have experienced in past 24 hours. Participants were asked to rate the severity of 6 disease-specific symptoms called mean module symptom severity (night sweats, fever \& chills, lymph node swelling, diarrhea, easy bruising/bleeding \& constipation). Each symptom is scored on scale from 0-10, where 0=not present \& 10=as bad as you can imagine. The total score across all questions (0 to 60) was divided by the number of questions. The mean score, therefore, ranged from 0-10. Higher scores indicated more symptom severity. FAS. Overall number analyzed=participants with data available for analysis. Number analyzed includes all with data at a given timepoint. Time frame continued: Day 28 After Completion/ET of VEN+G/Day 28 After TC/ET (FCR/BR)=Up to approximately 5.6 months; Change at Day 28 After TC/EC of Ven Monotherapy=Up to approximately 11 months.

Time frame:
Baseline, Day 22 of Cycle 1; Days 1, 2, & 22 of Cycle 2; Days 1 & 2 of Cycles 3, 4, 5; Day 1 of Cycles 6, 7, 8, 9, 10, 11 & 12; FU at Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 (1 cycle = 28 days)
Reported as:
Mean · score on a scale
Change From Baseline in Mean Module Symptom Severity Score as Measured by MDASI-CLL
score on a scaleArm A: VEN+GArm B: FCR/BR
Baseline1.63 ± 1.531.43 ± 1.28
Change at Cycle 1 Day 22-0.83 ± NA—
Change at Cycle 2 Day 1-0.67 ± 1.33-0.63 ± 1.81
Change at Cycle 2 Day 2—-0.58 ± 1.30
Change at Cycle 2 Day 22-1.50 ± NA—
Change at Cycle 3 Day 1-0.82 ± 1.27-0.80 ± 1.21
Change at Cycle 3 Day 2—-1.00 ± NA
Change at Cycle 4 Day 1-0.74 ± 1.19-1.01 ± 1.20
Change at Cycle 4 Day 2—-0.33 ± NA
Change at Cycle 5 Day 1-0.84 ± 1.29-0.94 ± 1.08
Change at Cycle 5 Day 2—-0.17 ± NA
Change at Cycle 6 Day 1-0.93 ± 1.21-0.86 ± 1.17
Change at Day 28 After Completion/Early Termination of Combination Therapy-0.21 ± 0.75—
Change at Day 28 After Treatment Completion or Early Termination-0.83 ± 1.18-0.90 ± 1.27
Change at Cycle 7 Day 1-0.87 ± 1.42—
Change at Cycle 8 Day 1-0.98 ± 1.29—
Change at Cycle 9 Day 1-1.00 ± 1.36—
Change at Cycle 10 Day 1-1.02 ± 1.34—
Change at Cycle 11 Day 1-1.07 ± 1.32—
Change at Cycle 12 Day 1-1.10 ± 1.41—
Change at Day 28 After Treatment Completion/Early Termination of Ven Monotherapy-1.05 ± 1.45—
Change at FU Month 3-1.78 ± 1.85-0.76 ± 1.29
Change at FU Month 6-1.20 ± 1.43-0.55 ± 1.35
Change at FU Month 9-1.23 ± 1.50-0.97 ± 1.38
Change at FU Month 12-1.05 ± 1.54-0.83 ± 1.15
Change at FU Month 15-1.15 ± 1.38-0.58 ± 1.18
Change at FU Month 18-1.03 ± 1.51-0.90 ± 1.34
Change at FU Month 21-0.94 ± 1.50-0.93 ± 1.09
Change at FU Month 24-0.93 ± 1.57-1.14 ± 1.30
Change at FU Month 27—-0.90 ± 1.20
Change at FU Month 30-1.23 ± 1.82—
Change at FU Month 33—-1.83 ± 1.33
Change at FU Month 360.50 ± NA—
SecondaryChange From Baseline in Mean Interference Score as Measured by MDASI-CLL

MDASI-CLL consists of 25 items over 3 scales that assess core cancer \& CLL-related symptom severity, and symptom interference that a participant may have experienced in past 24 hours. Participants rated 6 mean interference on life questions (general activity, walking, work, mood, relations with other people \& enjoyment of life) to derive the Mean Interference Score. These were scored on a scale from 0 (symptom did not interfere)-10 (symptom interfered completely). Total score across all questions (0 to 60) was divided by number of questions. Mean score, therefore, ranged from 0-10. Higher scores=higher symptom interference. FAS. Overall number analyzed=participants with data available for analysis. Number analyzed=participants with data available for analysis at a given timepoint. Time frame continued: Day 28 After Completion/ ET of Combination Therapy (VEN+G)/Day 28 After TC/ET (FCR/BR)=Up to approx 5.6 months; Change at Day 28 After TC/EC of Ven Monotherapy=Up to approx 11 months.

Time frame:
Baseline, Day 22 of Cycle 1; Days 1, 2, & 22 of Cycle 2; Days 1 & 2 of Cycles 3, 4, 5; Day 1 of Cycles 6, 7, 8, 9, 10, 11 & 12; FU at Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 (1 cycle = 28 days)
Reported as:
Mean · score on a scale
Change From Baseline in Mean Interference Score as Measured by MDASI-CLL
score on a scaleArm A: VEN+GArm B: FCR/BR
Baseline2.11 ± 2.182.17 ± 2.39
Change at Cycle 1 Day 221.33 ± NA—
Change at Cycle 2 Day 1-0.23 ± 1.91-0.29 ± 2.30
Change at Cycle 2 Day 2—0.17 ± 0.24
Change at Cycle 2 Day 22-1.67 ± NA—
Change at Cycle 3 Day 1-0.28 ± 2.22-0.51 ± 2.47
Change at Cycle 3 Day 2—0.33 ± NA
Change at Cycle 4 Day 1-0.29 ± 2.41-0.30 ± 2.53
Change at Cycle 4 Day 2—0.50 ± NA
Change at Cycle 5 Day 1-0.35 ± 2.38-0.43 ± 2.22
Change at Cycle 5 Day 2—2.00 ± NA
Change at Cycle 6 Day 1-0.52 ± 2.17-0.11 ± 2.45
Change at Day 28 After Completion/Early Termination of Combination Therapy-0.62 ± 4.40—
Change at Day 28 After Treatment Completion or Early Termination0.33 ± 0.94-0.63 ± 2.45
Change at Cycle 7 Day 1-0.01 ± 2.47—
Change at Cycle 8 Day 1-0.43 ± 2.37—
Change at Cycle 9 Day 1-0.13 ± 2.57—
Change at Cycle 10 Day 1-0.51 ± 2.49—
Change at Cycle 11 Day 1-0.54 ± 2.49—
Change at Cycle 12 Day 1-0.31 ± 2.22—
Change at Day 28 After Treatment Completion/Early Termination of Ven Monotherapy-0.33 ± 2.43—
Change at FU Month 30.47 ± 3.71-0.47 ± 2.50
Change at FU Month 6-0.27 ± 2.780.19 ± 2.82
Change at FU Month 9-0.60 ± 2.49-0.25 ± 2.13
Change at FU Month 12-0.40 ± 2.24-0.35 ± 2.20
Change at FU Month 15-0.34 ± 2.32-0.37 ± 2.02
Change at FU Month 18-0.54 ± 2.11-0.44 ± 2.28
Change at FU Month 21-0.21 ± 1.91-0.39 ± 2.05
Change at FU Month 24-0.75 ± 2.63-0.80 ± 1.97
Change at FU Month 27—-0.66 ± 2.11
Change at FU Month 30-1.08 ± 2.19—
Change at FU Month 33—-1.14 ± 2.90
Change at FU Month 362.00 ± NA—

Adverse events

Collected over Up to 56.4 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: VEN+G3/80 (3.8%)46/77 (59.7%)76/77 (98.7%)
Arm B: FCR/BR3/86 (3.5%)42/85 (49.4%)81/85 (95.3%)
Most frequent serious events
Showing 10 of 54
Most frequent serious events
EventArm A: VEN+GArm B: FCR/BR
Infusion related reactionInjury, poisoning and procedural complications9/776/85
PyrexiaGeneral disorders6/779/85
COVID-19Infections and infestations8/776/85
COVID-19 pneumoniaInfections and infestations7/775/85
Febrile neutropeniaBlood and lymphatic system disorders3/777/85
SepsisInfections and infestations1/774/85
PneumoniaInfections and infestations3/771/85
NeutropeniaBlood and lymphatic system disorders2/773/85
Atrial fibrillationCardiac disorders0/772/85
Neutrophil count decreasedInvestigations1/772/85
Most frequent other events
Showing 10 of 38
Most frequent other events
EventArm A: VEN+GArm B: FCR/BR
Infusion related reactionInjury, poisoning and procedural complications50/7735/85
NeutropeniaBlood and lymphatic system disorders43/7737/85
COVID-19Infections and infestations32/7727/85
ThrombocytopeniaBlood and lymphatic system disorders30/7718/85
NauseaGastrointestinal disorders16/7733/85
DiarrhoeaGastrointestinal disorders26/779/85
RashSkin and subcutaneous tissue disorders5/7723/85
VomitingGastrointestinal disorders4/7720/85
ConstipationGastrointestinal disorders7/7719/85
FatigueGeneral disorders9/7714/85

Baseline characteristics

Full Analysis Set (FAS) included all randomized participants, analyzed according to the treatment to which they were randomized.

Age, Continuous
Age, Continuous(years)Arm A: VEN+GArm B: FCR/BRTotal
Mean61.5 ± 9.161.0 ± 8.661.2 ± 8.8
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: VEN+GArm B: FCR/BRTotal
Female252954
Male5557112
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A: VEN+GArm B: FCR/BRTotal
Hispanic or Latino5510
Not Hispanic or Latino5062112
Unknown or Not Reported251944
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A: VEN+GArm B: FCR/BRTotal
American Indian or Alaska Native011
Asian112
Native Hawaiian or Other Pacific Islander000
Black or African American101
White5873131
More than one race000
Unknown or Not Reported201131
08

Study locations

40 sites
  • Medical Center of Aurora
    Aurora, Colorado 80012, United States
  • American Oncology Partners of Maryland, PA
    Bethesda, Maryland 20817, United States
  • University of Tennessee Medical Center;Office of Clinical Trials
    Knoxville, Tennessee 37920, United States
  • Oncology & Hematology Associates of Southwest Virginia, Inc._Goldschmidt
    Roanoke, Virginia 24014, United States
  • Canberra Hospital
    Canberra, Australian Capital Territory 2605, Australia
  • Liverpool Hospital
    Liverpool, New South Wales 2170, Australia
  • Port Macquarie - Mid North Coast Cancer Institute
    Port Macquarie, New South Wales 2444, Australia
  • Royal North Shore Hospital
    St Leonards, New South Wales 2065, Australia
  • Royal Hobart Hospital
    Hobart, Tasmania 7000, Australia
  • Monash Health;Haematology Research
    Clayton, Victoria 3168, Australia
  • Peter MacCallum Cancer Centre;Clinical Haematology
    Melbourne, Victoria 3050, Australia
  • Northern Hospital;Oncology and/or Hematology
    Melbourne, Victoria 3076, Australia
  • Hopital Haut Leveque Chu de Bordeaux
    Pessac, Aquitaine 33600, France
  • Centre Hospitalier Régional Universitaire de Tours - Hôpital Bretonneau;Hématologie et Thérapie Cellulaire
    Tours, Indre-et-Loire 37032, France
  • Centre Hospitalier de Pérpignan;hématologie
    Perpignan, Languedoc-Roussillon 66046, France
  • Hopital Claude Huriez - CHU de Lille;service maladies appareil digestif
    Lille, Nord 59037, France
  • Centre Hospitalier intercommunal de Toulon La Seyne sur Mer
    Toulon, Provence-Alpes-Côte d'Azur Region 83100, France
  • centre hospitalier lyon sud;Service Hématologie
    Pierre-Bénite, Rhône 69310, France
  • HENRI MONDOR HOSPITAL;Centre d'investigation clinique
    Créteil, Val-de-Marne 94000, France
  • Centre Hospitalier Universitaire de Caen Normandie
    Caen, 14000, France
  • Clinique Victor Hugo- CCS du Mans
    Le Mans, 72000, France
  • Centre Hospitalier Universitaire de Poitiers
    Poitiers, 86021, France
  • Centre Hospitalier Universitaire de Reims - Hôpital Robert Debré;Hématologie Clinique
    Reims, 51092, France
  • Instituto Tumori Giovanni Paolo II;ONCOLOGIA MEDICA
    Bari, Apulia 70124, Italy
  • Ospedale Vito Fazzi;U.O. Ematologia IV Piano Polo Oncologico
    Lecce, Apulia 73100, Italy
  • Azienda Ospedaliero Universitaria;Ematologia
    Modena, Emilia-Romagna 41125, Italy
  • Policlinico Umberto I
    Rome, Lazio 161, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli
    Rome, Lazio 168, Italy
  • Ospedale San Martino;U.O. Clinica Ematologica
    Genoa, Liguria 16132, Italy
  • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico;U.O.C Ematologia
    Milan, Lombardy 20122, Italy
  • ASST Grande Ospedale Metropolitano Niguarda;Ematologia
    Milan, Lombardy 20162, Italy
  • Azienda Ospedaliero Universitaria Maggiore della Carità;SCDU Ematologia
    Novara, Piedmont 28100, Italy
  • AO Santa Maria della Misericordia
    Perugia, Umbria 6132, Italy
  • Hospital Germans Trias i Pujol
    Badalona, Barcelona 8916, Spain
  • COMPLEJO HOSPITALARIO DE NAVARRA;Servicio de Hematología
    Pamplona, Navarre 31008, Spain
  • Hospital Universitari Vall d'Hebron;Hematology
    Barcelona, 8035, Spain
  • Hospital Universitario La Paz;Hematología
    Madrid, 28015, Spain
  • Hospital General Universitario Morales Meseguer;Hematologia y Oncologia médica
    Murcia, 30008, Spain
  • Hospital Universitario Virgen del Rocío;Unidad Onco-Hematología Pediátrica
    Seville, 41009, Spain
  • Hospital Universitario de Toledo
    Toledo, 45007, Spain
09

References and documents

Publications

  • Sharman JP, Laurenti L, Ferrant E, Casado Montero LF, Mulligan SP, Harrup R, Opat S, Ibatici A, Marasca R, Sportoletti P, Thadani-Mulero M, Cazares O, Huang W, Jiang Y, Clark E, Jin HY, Boyer M, Morschhauser F. Fixed-duration VenO vs FCR/BR in fit patients with untreated CLL: primary analysis of the phase 3 CRISTALLO trial. Blood. 2026 Jun 11;147(24):2895-2904. doi: 10.1182/blood.2025030630. PubMed 41770817 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to individual patient level data through the request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/innovation/process/clinical-trials/data-sharing).

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2020 to primary completion in Mar 2024, 45 months.

Results were first posted in Apr 2025, 1 year after primary completion.

Of 57 industry-sponsored phase 3 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 73. This study's 45 months is below that.

Counting every sponsor, half of 83 studies reached it within 59 months; a quarter within 43 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2020
First posted
Feb 26, 2020
StartActual
May 28, 2020
Primary completionActual
Mar 19, 2024
CompletionActual
Mar 19, 2025
Results first posted
Apr 17, 2025
Last update
Mar 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04285567
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Feb 26, 2020
Start date
May 28, 2020
Primary completion
Mar 19, 2024
Completion
Mar 19, 2025
Results posted
Apr 17, 2025
Last update
Mar 3, 2026

Study contacts

Clinical trial
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Obinutuzumab · Venetoclax

Start the discussion